Ferring Acquires Rights to Seikagaku Treatment for Herniated Disc
Ferring Pharmaceuticals acquired exclusive development and commercialization rights to Seikagaku’s SI-6603 injectable condoliase, a potential treatment for lumbar disc herniation, for up to US $95.0MM in upfront cash plus milestone payments. Aug 29, 2016